CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research report issued on Thursday. The firm set a “sell” rating on the stock.

CEL-SCI Price Performance

NYSE:CVM opened at $0.40 on Thursday. The firm has a market capitalization of $29.84 million, a price-to-earnings ratio of -0.69 and a beta of 0.65. CEL-SCI has a 1 year low of $0.36 and a 1 year high of $3.08. The business has a 50 day simple moving average of $0.57 and a 200-day simple moving average of $0.92. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.64 and a quick ratio of 0.18.

Institutional Investors Weigh In On CEL-SCI

Institutional investors have recently modified their holdings of the stock. Calton & Associates Inc. bought a new stake in shares of CEL-SCI in the 3rd quarter valued at approximately $50,000. Plotkin Financial Advisors LLC bought a new stake in shares of CEL-SCI during the 3rd quarter worth approximately $98,000. Thoroughbred Financial Services LLC lifted its stake in shares of CEL-SCI by 140.9% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock worth $158,000 after acquiring an additional 80,001 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after acquiring an additional 53,879 shares during the last quarter. 12.08% of the stock is owned by institutional investors.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.